European Journal of Surgical Oncology
Volume 34, Issue 6 , Pages 609-614 , June 2008

Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases

  • G. Morris-Stiff

      Affiliations

    • Department of Hepatobiliary Surgery, St James Hospital, Leeds, UK
    • Corresponding Author InformationCorresponding author: Mr Gareth Morris-Stiff. 1 Golygfa'r Eglwys, Maesycoed, Pontypridd, Rhondda Cynon Taf CF37 1JL, UK. Tel.: +44 01443 650 625.
    • ,
  • Y.-M. Tan

      Affiliations

    • Department of Hepatobiliary Surgery, Singapore General Hospital, Singapore
    • ,
  • J.N. Vauthey

      Affiliations

    • Department of Surgical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA

,Accepted 16 July 2007.

References 

  1. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–766
  2. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcome following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–827
  3. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography. Ann Surg. 2004;240:438–447
  4. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–722
  5. National Institute for Health and Clinic Excellence. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. www.nice.org.uk/TA093guidance.
  6. ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18(Suppl 2):25–26
  7. Gruenberger T, Sorbye H, Dubois M, et al. Tumour response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomised phase III trial. J Clin Oncol. 2006;24:3500
  8. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol. 2007;25:[Abstract LBA5]
  9. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–522
  10. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long-term survival. Ann Surg. 2004;240:644–658
  11. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038–2048
  12. Folprecht GA, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–1319
  13. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–37
  14. Willmot FC, Robertson GW. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet. 1920;2:848–849
  15. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible model of hepatic veno-occlusive disease. Hepatology. 1999;29:1779–1791
  16. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466
  17. Tisman G, MacDonald D, Shindell N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol. 2004;22:3202–3204
  18. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7
  19. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in ninety-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072
  20. Julie C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: Results of the EORTC Intergroup phase III study 40983. J Clin Oncol. 2007;25:[Abstract 241]
  21. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–4990
  22. Washington K, Lane KL, Meyers WC. Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol. 1993;17:1151–1158
  23. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc. 1995;9:561–576
  24. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136–1143
  25. Kooby DA, Fong Y, Suriawinata A, et al. Impact of perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034–1044
  26. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728
  27. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology. 2005;41:1313–1321
  28. Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg. 2006;243:8–9
  29. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77:2008–2011
  30. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irrinotecan or oxaliplatin on respectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–853
  31. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following resection for colorectal metastases. Ann Surg. 2003;237:860–870
  32. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2:292–298
  33. Belghiti J, Hiramatsu K, Benosit S, Massault PP, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38–46
  34. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474
  35. Selzner M, Rudiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology. 2000;32:1280–1288
  36. Koneru B, Dikdan G. Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation. 2002;73:325–330
  37. Jones OM, Rees M, John TG, Bygrave S, Plant G. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg. 2005;92:1165–1168
  38. Fiorini RN, Kirtz J, Periyasamy B, et al. Development of an unbiased method for the estimation of liver steatosis. Clin Transplant. 2004;18:700–706
  39. Vauthey J-N, Chaoui A, Do K-A, et al. Standardized measurement of the future liver remnant prior to extended resection: methodology and clinical associations. Surgery. 2000;127:512–519
  40. Mullin EJ, Metcalfe MS, Maddern GJ. How much liver resection is too much?. Am J Surg. 2005;190:87–97
  41. Oliva MR, Mortele KJ, Segatto E, et al. Computed tomography features of non-alcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr. 2006;30:37–43
  42. Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86:4–9
  43. Benoist S, Broquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol. 2006;24:3939–3945
  44. Welsh FKS, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037–1042
  45. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey J-N. Extended hepatectomy in patients with hepatobiliary malignancies with and without portal vein embolization. Arch Surg. 2002;137:675–681
  46. Vauthey J-N, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified?. Ann Surg. 2004;239:722–732
  47. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107:521–527
  48. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res. 2001;96:173–182
  49. Assy N, Spira G, Paizi M, et al. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol. 1999;30:911–915
  50. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005;23:4853–4855

PII: S0748-7983(07)00279-X

doi: 10.1016/j.ejso.2007.07.007

European Journal of Surgical Oncology
Volume 34, Issue 6 , Pages 609-614 , June 2008

Article Tools